Kyverna, ElevateBio Join Hands To Advance CAR T-cell Therapies

Kyverna Therapeutics, a clinical-stage cell therapy company focused on engineering a new class of therapies for serious autoimmune diseases, and ElevateBio, LLC, a technology-driven company focused on powering transformative cell and gene therapies, announced a collaboration to advance process development and manufacturing of industry-leading Ingenui-T-derived chimeric antigen receptor (CAR)T-cell therapies.

Kyverna developed Ingenui-T, an optimized autologous manufacturing platform, to especially answer the demands of patients with autoimmune illnesses, resulting in decreased costs of goods and an improved patient experience. ElevateBio and Kyverna will implement Kyverna’s Ingenui-T platform into their process development and cell product manufacturing efforts at ElevateBio BaseCamp. BaseCamp is ElevateBio’s end-to-end genetic medicine current Good Manufacturing Practice (cGMP) manufacturing and process development business with capabilities for research, clinical, and commercial cell and gene therapies, as per pharmabiz. Building and improving on the learnings from CAR T-cell therapy in oncology, Kyverna is seeking to revolutionize the way patients with autoimmune diseases are treated.

“We are excited by the potential to not only provide dramatic benefit to patients by eliminating the underlying disease pathology using CAR T-cell therapy, but also to bring innovation to other aspects of the patient journey,” said Karen Walker, chief technology officer at Kyverna. “Together with ElevateBio, we aim to deliver radical benefits to patients in less time, with lower impact, and at substantially reduced cost.” “At ElevateBio, we have combined multiple next-generation technology platforms with industry-leading expertise to transform the current cell and gene therapy development paradigm,” said Michael Paglia, chief operating officer at ElevateBio BaseCamp. “We are delighted to build a long-term relationship with Kyverna to optimize manufacturing processes and accelerate the development of their therapies.”